References
- Akhurst RJ, Derynck, R. (2001). TGF-beta signaling in cancer–a double-edged sword. Trends Cell Biol, 11(11), S44S51.
- Arico S, Pattingre S, Bauvy C, et al. (2002). Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem, 277(31), 27613–27621.
- Arpaia N, Campbell C, Fan X, et al. (2013). Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. Nature 504(7480), 451–455.
- Attisano L, Wrana JL. (2002). Signal transduction by the TGF-beta superfamily. Science, 296(5573), 1646–1647.
- Azzam HS, DeJarnette JB, Huang K, et al. (2001). Fine tuning of TCR signaling by CD5. J Immunology, 166(9), 5464–5472.
- Balkwill F, Mantovani A. (2001). Inflammation and cancer: back to Virchow? Lancet, 357(9255), 539–545.
- Becker C, Fantini MC, Schramm C, et al. (2004). TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity, 21(4), 491–501.
- Beissert S, Schwarz T. (1999). Mechanisms involved in ultraviolet light-induced immunosuppression. J Investig Dermatol Symp Proc, 4(1), 61–64.
- Bennett CL, Christie J, Ramsdell F, et al. (2001). The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet, 27(1), 20–21.
- Berg DJ, Davidson N, Kuhn R, et al. (1996). Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest, 98(4), 1010–1020.
- Bettelli E, Carrier Y, Gao W, et al. (2006). Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature, 441(7090), 235–238.
- Bhowmick NA, Chytil A, Plieth D, et al. (2004). TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science, 303(5659), 848–851.
- Bhowmick NA, Neilson EG, Moses HL. (2004). Stromal fibroblasts in cancer initiation and progression. Nature, 432(7015), 332–337.
- Bollrath J, Phesse TJ, von Burstin VA, et al. (2009). gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell, 15(2), 91–102.
- Bopp T, Becker C, Klein M, et al. (2007). Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med, 204(6), 1303–1310.
- Borsellino G, Kleinewietfeld M, Di Mitri D, et al. (2007). Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood, 110(4), 1225–1232.
- Brunkow ME, Jeffery EW, Hjerrild KA, et al. (2001). Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet, 27(1), 68–73.
- Burchill M.A, Yang J, Vogtenhuber C, et al. (2007). IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol, 178(1), 280–290.
- Calon A, Espinet E, Palomo-Ponce S, et al. (2012). Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell, 22(5), 571–584.
- Carter JD, Calabrese GM, Naganuma M, Lorenz U. (2005). Deficiency of the Src homology region 2 domain-containing phosphatase 1 (SHP-1) causes enrichment of CD4+CD25+ regulatory T cells. J Immunol, 174(11), 6627–6638.
- Chatila TA, Blaeser F, Ho N, et al. (2000). JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest, 106(12), R75–81.
- Chaudhry A, Samstein RM, Treuting P, et al. (2011). Interleukin-10 signaling in regulatory T cells is required for suppression of Th17 cell-mediated inflammation. Immunity, 34(4), 566–578.
- Chen L, Flies DB. (2013). Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol, 13(4), 227–242.
- Chen W, Jin W, Hardegen N, et al. (2003). Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med, 198(12), 1875–1886.
- Chen WS, Liu JH, Wei SJ, et al. (2003). Colon cancer cells with high invasive potential are susceptible to induction of apoptosis by a selective COX-2 inhibitor. Cancer Sci, 94(3), 253–258.
- Cho ML, Kang JW, Moon YM, et al. (2006). STAT3 and NF-kappaB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J Immunol, 176(9), 5652–5661.
- Choi PM, Zelig MP. (1994). Similarity of colorectal cancer in Crohn’s disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut, 35(7), 950–954.
- Collison LW, Workman CJ, Kuo TT, et al. (2007). The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature, 450(7169), 566–569.
- Correa P, Pickle LW, Fontham E, et al. (1983). Passive smoking and lung cancer. Lancet, 2(8350), 595–597.
- Coussens LM, Werb Z. (2002). Inflammation and cancer. Nature 420(6917), 860–867.
- Curran MA, Montalvo W, Yagita H, Allison JP. (2010). PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA, 107(9), 4275–4280.
- Dasu T, Qualls JE, Tuna H, et al. (2008). CD5 plays an inhibitory role in the suppressive function of murine CD4(+) CD25(+) T(reg) cells. Immunol Lett, 119(1–2), 103–113.
- Davidson NJ, Leach MW, Fort MM, et al. (1996). T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice. J Exp Med, 184(1), 241–251.
- Davis MM, Bjorkman PJ. (1988). T-cell antigen receptor genes and T-cell recognition. Nature, 334(6181), 395–402.
- Dennis KL, Wang Y, Blatner NR, et al. (2013). Adenomatous polyps are driven by microbe-instigated focal inflammation and are controlled by IL-10-producing T cells. Cancer Res, 73(19), 5905–5913.
- Derynck R, Akhurst RJ, Balmain A. (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet, 29(2), 117–129.
- de Visser KE, Eichten A, Coussens LM. (2006). Paradoxical roles of the immune system during cancer development. Nat Rev Cancer, 6(1), 24–37.
- DiDonato JA, Mercurio F, Karin M. (2012). NF-kappaB and the link between inflammation and cancer. Immunol Rev, 246(1), 379–400.
- Doll R. (1993). Mortality from lung cancer in asbestos workers 1955. Br J Ind Med, 50(6), 485–490.
- Doll R, Hill AB. (1956). Lung cancer and other causes of death in relation to smoking; a second report on the mortality of British doctors. Br Med J, 2(5001), 1071–1081.
- Dunn GP, Bruce AT, Ikeda H, et al. (2002). Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol, 3(11), 991–998.
- Eaden JA, Abrams KR, Mayberry JF. (2001). The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut, 48(4), 526–535.
- Ekbom A, Helmick C, Zack M, Adami HO. (1990a). Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet, 336(8711), 357–359.
- Ekbom A, Helmick C, Zack M, Adami HO. (1990b). Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med, 323(18), 1228–1233.
- Elinav E, Nowarski R, Thaiss CA, et al. (2013). Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer, 13(11), 759–771.
- El-Serag HB. (2012). Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 142(6), 1264–1273 e1261.
- Erdman SE, Poutahidis T, Tomczak M, et al. (2003). CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am J Pathol, 162(2), 691–702.
- Erdman SE, Rao VP, Poutahidis T et al. (2003). CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice. Cancer Res, 63(18), 6042–6050.
- Erdman SE, Sohn JJ, Rao VP, et al. (2005). CD4+CD25+ regulatory lymphocytes induce regression of intestinal tumors in ApcMin/+ mice. Cancer Res, 65(10), 3998–4004.
- EUROGAST Study Group. (1993). An international association between Helicobacter pylori infection and gastric cancer. The EUROGAST Study Group. Lancet 341(8857), 1359–1362.
- Fehervari Z, Sakaguchi S. (2004). Development and function of CD25+CD4+ regulatory T cells. Curr Opin Immunol, 16(2), 203–208.
- Fiorentino DF, Zlotnik A, Mosmann TR, et al. (1991). IL-10 inhibits cytokine production by activated macrophages. J Immunol, 147(11), 3815–3822.
- Fiorentino DF, Zlotnik A, Vieira P, et al. (1991). IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol, 146(10), 3444–3451.
- Fontenot JD, Gavin MA, Rudensky AY. (2003). Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol, 4(4), 330–336.
- Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. (2005). A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol, 6(11), 1142–1151.
- Friedline RH, Brown DS, Nguyen H, et al. (2009). CD4+ regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J Exp Med, 206(2), 421–434.
- Furusawa Y, Obata Y, Fukuda S, et al. (2013). Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature, 504(7480), 446–450.
- Gao Y, Yang W, Pan M, et al. (2003). Gamma delta T cells provide an early source of interferon gamma in tumor immunity. J Exp Med, 198(3), 433–442.
- Glick AB. (2012). The role of TGFbeta signaling in squamous cell cancer: Lessons from mouse models. J Skin Cancer, 2012, 249063.
- Go C, Li P, Wang XJ. (1999). Blocking transforming growth factor beta signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis. Cancer Res, 59(12), 2861–2868.
- Goldberg MV, Drake CG. (2011). LAG-3 in cancer immunotherapy. Curr Top Microbiol Immunol, 344, 269–278.
- Gondek DC, Lu LF, Quezada SA, et al. (2005). Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol, 174(4), 1783–1786.
- Gounaris E, Blatner NR, Dennis K, et al. (2009). T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res, 69(13), 5490–5497.
- Grady WM, Myeroff LL, Swinler SE, et al. (1999). Mutational inactivation of transforming growth factor beta receptor type II in microsatellite stable colon cancers. Cancer Res, 59(2), 320–324.
- Greten FR, Eckmann L, Greten TF, et al. (2004). IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 118(3), 285–296.
- Grivennikov S, Karin E, Terzic J, et al. (2009). IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell, 15(2), 103–113.
- Grivennikov SI, Greten FR, Karin M. (2010). Immunity, inflammation, and cancer. Cell, 140(6), 883–899.
- Grivennikov SI, Karin M. (2010). Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev, 21(1), 11–19.
- Grivennikov SI, Wang K, Mucida D, et al. (2012). Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature, 491(7423), 254–258.
- Grosso JF, Kelleher CC, Harris TJ, et al. (2007). LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J Clin Invest, 117(11), 3383–3392.
- Hanahan D, Weinberg RA. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674.
- He G, Karin M. (2011). NF-kappaB and STAT3 - key players in liver inflammation and cancer. Cell Res, 21(1), 159–168.
- Heldin CH, Miyazono K, ten Dijke P. (1997). TGF-beta signalling from cell membrane to nucleus through SMAD proteins. Nature, 390(6659), 465–471.
- Hori S, Nomura T, Sakaguchi S. (2003). Control of regulatory T cell development by the transcription factor Foxp3. Science, 299(5609), 1057–1061.
- Hsieh CS, Liang Y, Tyznik AJ, et al. (2004). Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors. Immunity, 21(2), 267–277.
- Huang CT, Workman CJ, Flies D, et al. (2004). Role of LAG-3 in regulatory T cells. Immunity, 21(4), 503–513.
- Hughes JM, Weill H. (1991). Asbestosis as a precursor of asbestos related lung cancer: results of a prospective mortality study. Br J Ind Med, 48(4), 229–233.
- Ikeda H, Old LJ, Schreiber RD. (2002). The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev, 13(2), 95–109.
- Josefowicz SZ, Lu LF, Rudensky AY. (2012). Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol, 30, 531–564.
- Kalluri R, Zeisberg M. (2006). Fibroblasts in cancer. Nat Rev Cancer, 6(5), 392–401.
- Kaplan DH, Shankaran V, Dighe AS, et al. (1998). Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA, 95(13), 7556–7561.
- Karin M. (2006). NF-kappaB and cancer: Mechanisms and targets. Mol Carcinog, 45(6), 355–361.
- Karin M, Greten FR. (2005) NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol, 5(10), 749–759.
- Khansari N, Shakiba Y, Mahmoudi M. (2009). Chronic inflammation and oxidative stress as a major cause of age-related diseases and cancer. Recent Pat Inflamm Allergy Drug Discov, 3(1), 73–80.
- Khattri R, Cox T, Yasayko SA, Ramsdell F. (2003). An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol, 4(4), 337–342.
- Kim JM, Rasmussen JP, Rudensky AY. (2007). Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol, 8(2), 191–197.
- Kim KS, Hong SW, Han D, et al. (2016). Dietary antigens limit mucosal immunity by inducing regulatory T cells in the small intestine. Science, 351(6275), 858–863.
- Kimelman D, Kirschner M. (1987). Synergistic induction of mesoderm by FGF and TGF-beta and the identification of an mRNA coding for FGF in the early Xenopus embryo. Cell, 51(5), 869–877.
- Klein L, Kyewski B, Allen PM, Hogquist KA. (2014). Positive and negative selection of the T cell repertoire: what thymocytes see (and don’t see). Nat Rev Immunol, 14(6), 377–391.
- Kretschmer K, Apostolou I, Hawiger D, et al. (2005). Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol, 6(12), 1219–1227.
- Lamouille S, Xu J, Derynck R. (2014). Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol, 15(3), 178–196.
- Langowski JL, Zhang X, Wu L, et al. (2006). IL-23 promotes tumour incidence and growth. Nature, 442(7101), 461–465.
- Lathrop SK, Bloom SM, Rao SM, et al. (2011). Peripheral education of the immune system by colonic commensal microbiota. Nature, 478(7368), 250–254.
- Laurence A, Tato CM, Davidson TS, et al. (2007). Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity, 26(3), 371–381.
- Lenschow DJ, Walunas TL, Bluestone JA. (1996). CD28/B7 system of T cell costimulation. Annu Rev Immunol, 14, 233–258.
- Li MO, Wan YY, Flavell RA. (2007). T cell-produced transforming growth factor-beta1 controls T cell tolerance and regulates Th1- and Th17-cell differentiation. Immunity, 26(5), 579–591.
- Liu Y, Zhang P, Li J, et al. (2008). A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nat Immunol, 9(6), 632–640.
- Long M, Park SG, Strickland I, et al. (2009). Nuclear factor-kappaB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor. Immunity, 31(6), 921–931.
- Loser K, Apelt J, Voskort M, et al. (2007). IL-10 controls ultraviolet-induced carcinogenesis in mice. J Immunol, 179(1), 365–371.
- Lu SL, Herrington H, Reh D, et al. (2006). Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev, 20(10), 1331–1342.
- Mantel PY, Ouaked N, Ruckert B, et al. (2006). Molecular mechanisms underlying FOXP3 induction in human T cells. J Immunol, 176(6), 3593–3602.
- Mantovani A, Allavena P, Sica A, Balkwill F. (2008). Cancer-related inflammation. Nature, 454(7203), 436–444.
- Markowitz S, Wang J, Myeroff L, et al. (1995). Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science, 268(5215), 1336–1338.
- Markowitz SD, Roberts AB. (1996). Tumor suppressor activity of the TGF-beta pathway in human cancers. Cytokine Growth Factor Rev, 7(1), 93–102.
- Massague J, Chen YG. (2000). Controlling TGF-beta signaling. Genes Dev, 14(6), 627–644.
- Melero I, Berman DM, Aznar MA, et al. (2015). Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer, 15(8), 457–472.
- Mittal P, St Rose MC, Wang X, et al. (2015). Tumor-unrelated CD4 T cell help augments CD134 plus CD137 dual costimulation tumor therapy. J Immunol, 195(12), 5816–5826.
- Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. (2001). Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol, 19, 683–765.
- Moore RJ, Owens DM, Stamp G, et al. (1999). Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med, 5(7), 828–831.
- Moses HL, Yang EY, Pietenpol JA. (1990). TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell, 63(2), 245–247.
- Nicholl MB, Ledgewood CL, Chen X, et al. (2014). IL-35 promotes pancreas cancer growth through enhancement of proliferation and inhibition of apoptosis: evidence for a role as an autocrine growth factor. Cytokine, 70(2), 126–133.
- Nishio J, Honda K. (2012). Immunoregulation by the gut microbiota. Cell Mol Life Sci, 69(21), 3635–3650.
- Oppmann B, Lesley R, Blom B, et al. (2000). Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity, 13(5), 715–725.
- Oshima M, Dinchuk JE, Kargman SL, et al. (1996). Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87(5), 803–809.
- Pacholczyk R, Ignatowicz H, Kraj P, Ignatowicz L. (2006). Origin and T cell receptor diversity of Foxp3+CD4+CD25+ T cells. Immunity, 25(2), 249–259.
- Pardoll DM. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer, 12(4), 252–264.
- Perez-Villar JJ, Whitney GS, Bowen MA, et al. (1999). CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1. Mol Cell Biol, 19(4), 2903–2912.
- Rebouissou S, Amessou M, Couchy G, et al. (2009). Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature, 457(7226), 200–204.
- Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. (2010). Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med, 49(11), 1603–1616.
- Rubtsov YP, Rasmussen JP, Chi EY, et al. (2008). Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity, 28(4), 546–558.
- Sakaguchi S. (2000). Regulatory T cells: key controllers of immunologic self-tolerance. Cell, 101(5), 455–458.
- Sakaguchi S, Sakaguchi N, Asano M, et al. (1995). Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol, 155(3), 1151–1164.
- Salomon B, Lenschow DJ, Rhee L, et al. (2000). B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity, 12(4), 431–440.
- Schmidt-Supprian M, Tian J, Grant EP, et al. (2004). Differential dependence of CD4+CD25+ regulatory and natural killer-like T cells on signals leading to NF-kappaB activation. Proc Natl Acad Sci USA, 101(13), 4566–4571.
- Schreiber RD, Old LJ, Smyth MJ. (2011). Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science, 331(6024), 1565–1570.
- Schumacher TN, Schreiber RD. (2015). Neoantigens in cancer immunotherapy. Science, 348(6230), 69–74.
- Schwartz RH. (2003). T cell anergy. Annu Rev Immunol, 21, 305–334.
- Selby MJ, Engelhardt JJ, Quigley M, et al. (2013). Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res, 1(1), 32–42.
- Sen G, Bikah G, Venkataraman C, Bondada S. (1999). Negative regulation of antigen receptor-mediated signaling by constitutive association of CD5 with the SHP-1 protein tyrosine phosphatase in B-1 B cells. Eur J Immunol, 29(10), 3319–3328.
- Shattuck-Brandt RL, Varilek GW, Radhika A, et al. (2000). Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(−/−) mice. Gastroenterology, 118(2), 337–345.
- Singh A, Singh A, Bauer SJ, et al. (2016). Genetic deletion of TNFalpha inhibits ultraviolet radiation-induced development of cutaneous squamous cell carcinomas in PKCepsilon transgenic mice via inhibition of cell survival signals. Carcinogenesis, 37(1), 72–80.
- Starr TK, Jameson SC, Hogquist KA. (2003). Positive and negative selection of T cells. Annu Rev Immunol, 21, 139–176.
- Street SE, Cretney E, Smyth MJ. (2001). Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood, 97(1), 192–197.
- Swann JB, Smyth MJ. (2007). Immune surveillance of tumors. J Clin Invest, 117(5), 1137–1146.
- Tai X, Cowan M, Feigenbaum L, Singer A. (2005). CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol, 6(2), 152–162.
- Taniguchi K, Wu LW, Grivennikov SI, et al. (2015). A gp130-Src-YAP module links inflammation to epithelial regeneration. Nature, 519(7541), 57–62.
- Thiery JP. (2003). Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol, 15(6), 740–746.
- Trinchieri G, Pflanz S, Kastelein RA. (2003). The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity, 19(5), 641–644.
- Turnis ME, Sawant DV, Szymczak-Workman AL, et al. (2016). Interleukin-35 limits anti-tumor immunity. Immunity, 44(2), 316–329.
- Vang KB, Yang J, Mahmud SA, et al. (2008). IL-2, -7, and -15, but not thymic stromal lymphopoeitin, redundantly govern CD4+Foxp3+ regulatory T cell development. J Immunol, 181(5), 3285–3290.
- Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. (2011). Natural innate and adaptive immunity to cancer. Annu Rev Immunol, 29, 235–271.
- Vignali DA, Collison LW, Workman CJ. (2008). How regulatory T cells work. Nat Rev Immunol, 8(7), 523–532.
- Vignali DA, Kuchroo VK. (2012). IL-12 family cytokines: immunological playmakers. Nat Immunol, 13(8), 722–728.
- Wang CY, Eshleman JR, Willson JK, Markowitz S. (1995). Both transforming growth factor-beta and substrate release are inducers of apoptosis in a human colon adenoma cell line. Cancer Res, 55(21), 5101–5105.
- Wang K, Karin M. (2015). Tumor-elicited inflammation and colorectal cancer. Adv Cancer Res, 128, 173–196.
- Wang Z, Liu JQ, Liu Z, et al. (2013). Tumor-derived IL-35 promotes tumor growth by enhancing myeloid cell accumulation and angiogenesis. J Immunol, 190(5), 2415–2423.
- Wildin RS, Smyk-Pearson S, Filipovich AH. (2002). Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet, 39(8), 537–545.
- Williams LM, Rudensky AY. (2007). Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat Immunol, 8(3), 277–284.
- Wing K, Onishi Y, Prieto-Martin P, et al. (2008). CTLA-4 control over Foxp3+ regulatory T cell function. Science, 322(5899), 271–275.
- Xu J, Lamouille S, Derynck R. (2009). TGF-beta-induced epithelial to mesenchymal transition. Cell Res, 19(2), 156–172.
- Yang X, Letterio JJ, Lechleider RJ, et al. (1999). Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J, 18(5), 1280–1291.
- Yu H, Jove R. (2004). The STATs of cancer–new molecular targets come of age. Nat Rev Cancer, 4(2), 97–105.
- Yu H, Kortylewski M, Pardoll D. (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol, 7(1), 41–51.
- Yusuf N, Nasti TH, Katiyar SK, et al. (2008). Antagonistic roles of CD4+ and CD8+ T-cells in 7,12-dimethylbenz(a)anthracene cutaneous carcinogenesis. Cancer Res, 68(10), 3924–3930.
- Zhao DM, Thornton AM, DiPaolo RJ, Shevach EM. (2006). Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood, 107(10), 3925–3932.
- Zheng SG, Wang JH, Gray JD, et al. (2004). Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: The role of IL-2, TGF-beta, and IL-10. J Immunol, 172(9), 5213–5221.